BioNTech SE's partner, MediLink, reported a partial clinical hold by the FDA on their trial for the drug BNT326/YL202 aimed at treating certain cancers, affecting patient enrollment in the U.S. The hold is due to safety concerns, particularly at higher doses. Date of filing: June 17, 2024.